ArticleBMC microbiology2010
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Article in BMC microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 53 citations in OpenAlex.
- Article
- Adaptive laboratory-evolved MRSA with PPEF manifests cross-susceptibility to oxacillin and hypersensitivity to ciprofloxacin.Microbiology spectrum · 2025Article
- Navigating fluoroquinolone resistance in Gram-negative bacteria: a comprehensive evaluation.JAC-antimicrobial resistance · 2024Review
- Genomic alterations involved in fluoroquinolone resistance development in Staphylococcus aureus.PloS one · 2023Article
- Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice-The "AIOLOS" Study.Canadian respiratory journal · 2021Observational
- Investigation of In-Vitro Adaptation toward Sodium Bituminosulfonate inMicroorganisms · 2020Article
- Characterization of Extremely Drug-Resistant and HypervirulentAntibiotics (Basel, Switzerland) · 2020Article
- Multiple Drug Resistance Patterns in Various Phylogenetic Groups of Hospital-Acquired UropathogenicAntibiotics (Basel, Switzerland) · 2020Article
- Article
- Urinary Tract Infections: Resistance Is Futile.Antimicrobial agents and chemotherapy · 2016Article
- Antibiotic resistance and genotype of beta-lactamase producing Escherichia coli in nosocomial infections in Cotonou, Benin.Annals of clinical microbiology and antimicrobials · 2015Article
- Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal.Antimicrobial resistance and infection control · 2015Article
- Dynamics of quinolone resistance in fecal Escherichia coli of finishing pigs after ciprofloxacin administration.The Journal of veterinary medical science · 2014Article
- Comparison of phenotypic characteristics and antimicrobial resistance patterns of clinical Escherichia coli collected from two unrelated geographical areas.Global journal of health science · 2014Article
- Molecular analysis of ciprofloxacin resistance mechanisms in Malaysian ESBL-producing Klebsiella pneumoniae isolates and development of mismatch amplification mutation assays (MAMA) for rapid detection of gyrA and parC mutations.BioMed research international · 2014Article
- Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli.BMC infectious diseases · 2013Article
- Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, Sudan.African health sciences · 2012Article
- The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Review
- Macrolide resistance and in vitro selection of resistance to antibiotics in Lactobacillus isolates.Journal of microbiology (Seoul, Korea) · 2011Article
- Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy.Infection and drug resistance · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFluoroquinolones are potent antimicrobial agents used for the treatment of a wide variety of community- and nosocomial- infections. However, resistance to fluoroquinolones in Enterobacteriaceae is increasingly reported. Studies assessing the ability of fluoroquinolones to select for resistance have often used antimicrobial concentrations quite different from those actually acquired at the site of infection. The present study compared the ability to select for resistance of levofloxacin, ciprofloxacin and prulifloxacin at concentrations observed in vivo in twenty strains of Escherichia coli and Klebsiella spp. isolated from patients with respiratory and urinary infections. The frequencies of spontaneous single-step mutations at plasma peak and trough antibiotic concentrations were calculated. Multi-step selection of resistance was evaluated by performing 10 serial cultures on agar plates containing a linear gradient from trough to peak antimicrobial concentrations, followed by 10 subcultures on antibiotic-free agar. E. coli resistant strains selected after multi-step selection were characterized for DNA mutations by sequencing gyrA, gyrB, parC and parE genes.
resultsFrequencies of mutations for levofloxacin and ciprofloxacin were less than 10-11 at peak concentration, while for prulifloxacin they ranged from <10-11 to 10-5. The lowest number of resistant mutants after multistep selection was selected by levofloxacin followed by ciprofloxacin and prulifloxacin. Both ciprofloxacin- and prulifloxacin-resistant mutants presented mutations in gyrA and parC, while levofloxacin resistance was found associated only to mutations in gyrA.
conclusionsAmong the tested fluoroquinolones, levofloxacin was the most capable of limiting the occurrence of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.